Physician profile
Robert S Gold
NPI 1093753824
$3,409.58
in general payments reported to CMS, 2019-2025
10 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 92% of Pediatric Ophthalmology and Strabismus Specialist providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.37 · 2020: $185 · 2021: $15.38 · 2022: $176 · 2023: $1,437 · 2024: $44.01 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Honoraria: $1,336 · Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Honoraria | $1,336.25 |
| Food and Beverage | $267.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luminopia, INC. | $1,400.00 | 2025 | Luminopia |
| Natus Medical Incorporated | $1,336.25 | 2023 | |
| Horizon Therapeutics Plc | $417.42 | 2020-2023 | Tepezza |
| Amgen INC. | $143.14 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $24.85 | 2020 | |
| Bausch & Lomb Americas INC. | $23.02 | 2025 | Vyzulta |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $16.12 | 2019 | |
| Alcon Vision LLC | $15.13 | 2023 | Hydrus Microstent |
| Spark Therapeutics, INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.